NEEDS REVIEW
As of October 29, 2026 at 1:49 PM, this is how Optics News reads the wording differences in this story.
What happened The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
The headline split The headlines are mostly aligned. The differences are small wording choices, not a major framing split.
Match confidence Watch. Only one source has this so far. Optics is waiting for broader pickup before scoring it.
Same-event confidenceDevelopingNot enough sources yet to confirm this is the same specific event.
Framing confidenceHiddenWording-gap score not shown — same-event match is still developing.
Wording differs, but the match is too narrow to read confidently yet.
WHAT EACH SIDE EMPHASIZED
Left / center-leftNo matching source in this bucket yet.Optics keeps watching for pickup.
CenterNo matching source in this bucket yet.Optics keeps watching for pickup.
Right / center-rightLilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.MarketWatch · Center-right · News report
SEE THE HEADLINES
Center-rightMostly FactualLilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
DetailsScore hidden · 1 sources · 1 bias buckets
Score hidden until the match is cleanerNeeds review confidence1 sources · 1 bias bucketsEarly pickup · awaiting comparisonFormats: News report
SOURCE MAP CHANGES
Oct 29, 1:49 PM: MarketWatch joined the source map.
Now: score hidden until the source match is cleaner. Story health is early pickup · awaiting comparison.